Anika Therapeutics 2022 Investor Overview

Anika Therapeutics presents its investor overview highlighting 30+ years of expertise in hyaluronic acid-based joint preservation and osteoarthritis pain management products. The company holds the #1 market position in HA-based OA pain management in the U.S. with a diversified portfolio spanning OA treatment, regenerative solutions, and sports medicine, supported by clinical pipelines including Hyalofast and Cingal trials.